Trends in allogeneic Stem cell transplantation for multiple myeloma: A CIBMTR analysis

Blood

Volumn 118, Issue 7, 2011, Pages 1979-1988

  Kumar, Shaji ^a   Zhang, Mei Jie ^b   Li, Peigang ^b   Dispenzieri, Angela ^a   Milone, Gustavo A ^c   Lonial, Sagar ^d   Krishnan, Amrita ^e   Maiolino, Angelo ^f   Wirk, Baldeep ^g   Weiss, Brendan ^h   Freytes, César O ⁱ   Vogl, Dan T ^j   Vesole, David H ^k   Lazarus, Hillard M ^l   Meehan, Kenneth R ^m   Hamadani, Mehdi ⁿ   Lill, Michael ^o   Callander, Natalie S ^p   Majhail, Navneet S ^q   Wiernik, Peter H ^r   Nath, Rajneesh ^s   Kamble, Rammurti T ^t   Vij, Ravi ^u   Kyle, Robert A ^a   Gale, Robert Peter ^v   Hari, Parameswaran N ^b   more..

^a MAYO CLINIC   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c Fundacion para Combatir La Leucemia   (Argentina)

^d EMORY UNIVERSITY HOSPITAL   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^g UNIVERSITY OF FLORIDA   (United States)

^h WALTER REED ARMY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^l UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^m DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

ⁿ WEST VIRGINIA UNIVERSITY HOSPITALS   (United States)

^o CEDARS SINAI MEDICAL CENTER   (United States)

^p University of Wisconsin Health   (United States)

^q UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^r ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^s UMASS MEMORIAL MEDICAL CENTER   (United States)

^t CENTER FOR CELL AND GENE THERAPY   (United States)

^u BARNES JEWISH HOSPITAL   (United States)

^v CELGENE CORPORATION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD DONOR; CANCER RELAPSE; CANCER SURVIVAL; CANCER TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; COHORT ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

EID: 80051878404     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-337329     Document Type: Article

References (34)

1. Kumar S.K., Mikhael J.R., Buadi F.K., et al. Management of newly diagnosed symptomatic multiple myeloma: Updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines. Mayo Clin Proc. 2009;84(12):1095-1110.
2. Giralt S., Stadtmauer E.A., Harousseau J.L., et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009;23(10):1904-1912.
3. Bensinger W.I. Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia. 2009;23(3):442-448.
4. Arora M., McGlave P.B., Burns L.J., et al. Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma. Bone Marrow Transplant. 2005;35(12):1133-1140. (Pubitemid 40895168)
5. Bjorkstrand B.B., Ljungman P., Svensson H., et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood. 1996;88(12):4711-4718. (Pubitemid 26419156)
6. Alyea E., Weller E., Schlossman R., et al. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: Impact of graft-versus-myeloma effect. Bone Marrow Transplant. 2003;32(12):1145-1151. (Pubitemid 38072327)
7. Kuruvilla J., Shepherd J.D., Sutherland H.J., et al. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2007;13(8):925-931. (Pubitemid 47064359)
8. Tricot G., Vesole D.H., Jagannath S., Hilton J., Munshi N., Barlogie B. Graft-versus-myeloma effect: Proof of principle. Blood. 1996;87(3):1196-1198. (Pubitemid 26043549)
9. Martinelli G., Terragna C., Zamagni E., et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol. 2000;18(11):2273-2281. (Pubitemid 30350220)
10. Cavo M., Terragna C., Martinelli G., et al. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood. 2000;96(1):355-357. (Pubitemid 30456493)
11. Corradini P., Cavo M., Lokhorst H., et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood. 2003;102(5):1927-1929. (Pubitemid 37022595)
12. Gahrton G., Svensson H., Cavo M., et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol. 2001;113(1):209-216. (Pubitemid 32423325)
13. Storek J., Gooley T., Siadak M., et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood. 1997;90(12):4705-4709.
14. Krishnan A., Pasquini M.C., Ewell M., et al. Tandem Autologous hematopoietic stem cell transplants (AuHCT) with or without maintenance therapy (auto-auto) versus single AuHCT followed by HLA matched sibling non-myeloablative allogeneic HCT (auto-allo) for patients with standard risk (SR) multiple myeloma (MM): Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 trial [abstract]. Blood. 2010;116(21):Abstract 41.
15. Stadtmauer E.A., Krishnan A., Pasquini M.C., et al. Tandem autologous stem cell transplants (autoauto) with or without maintenance therapy versus single autologous transplant followed by HLAmatched sibling non-myeloablative allogeneic stem cell transplant (auto-auto) for patients (pts) with high risk (HR) multiple myeloma (MM). results from the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0102 Trial [abstract]. Blood. 2010;116(21):Abstract 526.
16. Garban F., Attal M., Michallet M., et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006;107(9):3474-3480.
17. Bruno B., Rotta M., Patriarca F., et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356(11):1110-1120. (Pubitemid 46425595)
18. Lokhorst H., Einsele H., Vesole D., et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol. 28(29):4521-4530.
19. Gahrton G., Bjorkstrand B., Iacobelli S., et al. Tandem autologous(ASCT)/allogeneic reduced intensity conditioning transplantation (RIC) with identical sibling donor versus ASCT in previously untreated multiple myeloma (MM): Long term follow up of a prospective controlled trial by the EBMT [abstract]. Blood. 2009;114(22):Abstract 52.
20. Kumar S.K., Rajkumar S.V., Dispenzieri A., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516- 2520.
21. Brenner H., Gondos A., Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111(5):2521- 2526.
22. Le Blanc R., Montminy-Metivier S., Belanger R., et al. Allogeneic transplantation for multiple myeloma: Further evidence for a GVHD-associated graft-versus-myeloma effect. Bone Marrow Transplant. 2001;28(9):841-848. (Pubitemid 33107611)
23. Rosinol L., Perez-Simon J.A., Sureda A., et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood. 2008;112(9):3591-3593.
24. Gahrton G., Tura S., Ljungman P., et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med. 1991;325(18):1267-1273.
25. Gerull S., Goerner M., Benner A., et al. Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant. 2005;36(11):963-969. (Pubitemid 41741559)
26. Kroger N., Perez-Simon J.A., Myint H., et al. Relapse to prior autograft and chronic graft-versushost disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant. 2004;10(10):698-708. (Pubitemid 39272874)
27. Kroger N., Schilling G., Einsele H., et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood. 2004;103(11):4056-4061. (Pubitemid 38685344)
28. Schilling G., Hansen T., Shimoni A., et al. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia. 2008;22(6):1250-1255. (Pubitemid 351833794)
29. Fonseca R., Blood E., Rue M., et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101(11):4569-4575. (Pubitemid 36857829)
30. Gahrton G., Iacobelli S., Bandini G., et al. Peripheral blood or bone marrow cells in reducedintensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. Haematologica. 2007;92(11):1513-1518. (Pubitemid 350144127)
31. Crawley C., Lalancette M., Szydlo R., et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: An analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood. 2005;105(11):4532-4539. (Pubitemid 40720805)
32. Kroger N. Mini-Midi-Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation. Leukemia. 2007;21(9):1851-1858. (Pubitemid 47299957)
33. Giralt S., Aleman A., Anagnostopoulos A., et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2002;30(6):367-373. (Pubitemid 35203509)
34. Cavo M., Bandini G., Benni M., et al. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. Bone Marrow Transplant. 1998;22(1):27-32 (Pubitemid 28330532)